Skip to main content
Detailed chapter

Fatty Liver Disease

Steatosis, MASH, and metabolic risk

Fatty liver (hepatic steatosis) is fat buildup inside liver cells. It may be alcohol-related or metabolic-associated (MASLD — formerly NAFLD). When inflammation and damage progress (MASH — formerly NASH), fibrosis and cirrhosis can follow. Diabetes, obesity, and metabolic syndrome are common partners.

Fatty liver · educational illustration

Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.

© Cengiz Dibekoğlu — illustrative; not for unauthorized use

Figure summary

This educational figure shows: Fatty liver.

Key points

  • Who is at higher risk?

    Obesity, type 2 diabetes, insulin resistance, high triglycerides, and sedentary lifestyle raise risk. Alcohol is a separate steatosis pathway. Many people have no symptoms.

    • Obesity and diabetes
    • Insulin resistance
    • Alcohol excess
  • Symptoms and diagnosis

    Often silent; fatigue or mild right-upper discomfort may appear. Ultrasound is a frequent first finding; enzymes may rise. Elastography, MR, or biopsy may follow if fibrosis is suspected.

  • What helps?

    Weight loss, Mediterranean-style eating, exercise, glycemic and lipid control, and limiting alcohol. Medications are considered in selected cases. HCC surveillance matters if MASH cirrhosis develops.

  • Why fibrosis staging matters

    The degree of scarring—not just fat—drives long-term risk. Scores such as FIB-4 and elastography guide whether hepatology referral is needed.

This page is for education. It is not medical advice and does not replace a visit with your physician.

Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · Last medically reviewed: August 2026 · English patient-education chapter.